A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

← catalyst calendar

NCT06421636 · readout in 106 d

Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.

Phase

Phase 2

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

19actual

Sites

Countries

Georgia, Greece, India +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2024-09-30

actual

When the study began enrolling

Primary completion

2026-12-03

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2026-12-03

estimated

The whole study's end, after follow-up

First posted

2024-05-20

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-01

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Interventions

Drug: REGN7999
Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF

Change from baseline in Liver Iron Concentration (LIC) by R2* Magnetic Resonance Imaging (MRI)

measured At week 24

Incidence of Treatment-Emergent Adverse Events (TEAEs)

measured Up to week 72

Severity of TEAEs

measured Up to week 72

Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed